| 产品描述: | Theliatinib (Xiliertinib) 是一种有效、ATP 竞争性、口服活性和高度选择性的 EGFR 抑制剂,Ki 为 0.05 nM,IC50 为 3 nM。Theliatinib 对 EGFR T790M/L858R 突变体的 IC50 值为 22 nM。Theliatinib 对 EGFR 的选择性是其他激酶的 50 倍以上。抗肿瘤活性。 |
| 靶点: |
EGFR:3 nM (IC50);EGFR:0.05 nM (Ki);EGFR (L858R/T790M):22 nM (IC50) |
| 体外研究: |
Theliatinib significantly inhibits EGFR phosphorylation in A431 cells with an IC50 of 7 nM. Theliatinib also inhibits A431, H292 and FaDu cells survival with IC50 values of 80 nM, 58 nM and 354 nM, respectively. |
| 体内研究: |
Theliatinib (2-15 mg/kg; oral administration;daily; for 21 days; NOD-SCID mice; PDECX 1T0950 model) treatment demonstrates tumor regression of 75% at the end of study, and with a dose response. |
| 参考文献: |
1. Ren Y, et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. Oncotarget. 2017 Apr 19;8(31):50832-50844. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.26 ml |
11.299 ml |
22.598 ml |
| 5 mM |
0.452 ml |
2.26 ml |
4.52 ml |
| 10 mM |
0.226 ml |
1.13 ml |
2.26 ml |
| 50 mM |
0.045 ml |
0.226 ml |
0.452 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |